05:18:24 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.

Kalender

2022-08-25 Kvartalsrapport 2022-Q2
2022-07-07 Extra Bolagsstämma 2022
2022-04-25 Ordinarie utdelning FARON 0.00 EUR
2022-04-22 Årsstämma 2022
2022-03-25 Bokslutskommuniké 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-26 Ordinarie utdelning FARON 0.00 EUR
2021-04-23 Årsstämma 2021
2021-03-25 Bokslutskommuniké 2020
2020-05-14 Ordinarie utdelning FARON 0.00 EUR
2020-05-13 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019
2022-04-08 16:45:00

Faron Pharmaceuticals Ltd.
("Faron" or the "Company")

Managers' transactions

Company announcement, 8 April 2022 at 5:45 PM (EET) / 3:45 PM (GMT) / 10:45 AM (EDT) 

TURKU, FINLAND/BOSTON, MA- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces today that Dr Markku Jalkanen, Chief Executive Officer of the Company, acquired 25,000 ordinary shares in Faron at a volume weighted average price of €2.8213 per share on 5 April, 2022. Following these purchases, Dr Jalkanen directly holds 2,125,565 ordinary shares in the Company, representing 3.99 per cent. of the Company's issued share capital and has a combined interest with his spouse in 3,251,677 ordinary shares in the Company, representing 6.11 per cent of the Company's issued share capital.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.                           

Notification
of a
Transaction
pursuant to
Article
19(1) of
Regulation
(EU) No.
596/2014
1 Details of the person
discharging managerial
responsibilities/person
closely associated
a. Name Markku Jalkanen
2 Reason for notification
a. Position/Status Chief Executive
Officer
b. Initial notification/ Initial Notification

Amendment
3 Details of the issuer,
emission allowance market
participant, auction
platform, auctioneer or
auction monitor
a. Name Faron
Pharmaceuticals Oy
b. LEI 7437009H31TO1DC0EB42
4 Details of the
transaction(s): section to be
repeated for (i) each type of
instrument; (ii) each type of
transaction; (iii) each date;
and (iv) each place where
transactions have been
conducted
a. Description of the financial Ordinary shares
instrument, type of ISIN: FI4000153309
instrument
Identification Code
b. Nature of the transaction Purchase of ordinary
shares
c. Price(s) and volume(s) Average
Price(s) Volume(s)
€2.8213 25,000
Transaction
details

(1): Volume:
91 Unit
price: 2.84
EUR

(2): Volume:
167 Unit
price: 2.825
EUR

(3): Volume:
192 Unit
price: 2.825
EUR

(4): Volume:
16 Unit
price: 2.825
EUR

(5): Volume:
16 Unit
price: 2.825
EUR

(6): Volume:
509 Unit
price: 2.825
EUR

(7): Volume:
40 Unit
price: 2.825
EUR

(8): Volume:
116 Unit
price: 2.825
EUR

(9): Volume:
129 Unit
price: 2.825
EUR

(10):
Volume: 688
Unit price:
2.825 EUR

(11):
Volume: 192
Unit price:
2.825 EUR

(12):
Volume: 167
Unit price:
2.825 EUR

(13):
Volume: 16
Unit price:
2.825 EUR

(14):
Volume: 132
Unit price:
2.825 EUR

(15):
Volume: 169
Unit price:
2.825 EUR

(16):
Volume:
1,063 Unit
price: 2.825
EUR

(17):
Volume: 175
Unit price:
2.825 EUR

(18):
Volume: 283
Unit price:
2.825 EUR

(19):
Volume: 889
Unit price:
2.82 EUR

(20):
Volume: 97
Unit price:
2.82 EUR

(21):
Volume: 466
Unit price:
2.8 EUR

(22):
Volume:
1,487 Unit
price: 2.8
EUR

(23):
Volume:
1,267 Unit
price: 2.8
EUR

(24):
Volume: 97
Unit price:
2.8 EUR

(25):
Volume:
1,267 Unit
price: 2.8
EUR

(26):
Volume: 206
Unit price:
2.8 EUR

(27):
Volume: 77
Unit price:
2.82 EUR

(28):
Volume: 153
Unit price:
2.82 EUR

(29):
Volume: 40
Unit price:
2.82 EUR

(30):
Volume: 77
Unit price:
2.82 EUR

(31):
Volume: 14
Unit price:
2.82 EUR

(32):
Volume: 100
Unit price:
2.82 EUR

(33):
Volume: 17
Unit price:
2.82 EUR

(34):
Volume: 139
Unit price:
2.82 EUR

(35):
Volume: 14
Unit price:
2.82 EUR

(36):
Volume: 184
Unit price:
2.82 EUR

(37):
Volume: 55
Unit price:
2.82 EUR

(38):
Volume: 31
Unit price:
2.82 EUR

(39):
Volume: 55
Unit price:
2.82 EUR

(40):
Volume: 129
Unit price:
2.82 EUR

(41):
Volume: 86
Unit price:
2.82 EUR

(42):
Volume: 55
Unit price:
2.82 EUR

(43):
Volume: 98
Unit price:
2.82 EUR

(44):
Volume: 117
Unit price:
2.82 EUR

(45):
Volume: 153
Unit price:
2.82 EUR

(46):
Volume: 117
Unit price:
2.82 EUR

(47):
Volume: 153
Unit price:
2.82 EUR

(48):
Volume: 17
Unit price:
2.82 EUR

(49):
Volume: 100
Unit price:
2.82 EUR

(50):
Volume: 69
Unit price:
2.82 EUR

(51):
Volume: 184
Unit price:
2.82 EUR

(52):
Volume: 86
Unit price:
2.82 EUR

(53):
Volume: 86
Unit price:
2.82 EUR

(54):
Volume: 184
Unit price:
2.82 EUR

(55):
Volume: 98
Unit price:
2.82 EUR

(56):
Volume: 270
Unit price:
2.82 EUR

(57):
Volume: 270
Unit price:
2.82 EUR

(58):
Volume: 100
Unit price:
2.82 EUR

(59):
Volume: 270
Unit price:
2.82 EUR

(60):
Volume: 270
Unit price:
2.82 EUR

(61):
Volume: 68
Unit price:
2.835 EUR

(62):
Volume: 25
Unit price:
2.835 EUR

(63):
Volume: 17
Unit price:
2.835 EUR

(64):
Volume: 104
Unit price:
2.835 EUR

(65):
Volume: 43
Unit price:
2.835 EUR

(66):
Volume: 85
Unit price:
2.835 EUR

(67):
Volume: 14
Unit price:
2.835 EUR

(68):
Volume: 31
Unit price:
2.835 EUR

(69):
Volume: 18
Unit price:
2.835 EUR

(70):
Volume: 71
Unit price:
2.835 EUR

(71):
Volume: 9
Unit price:
2.835 EUR

(72):
Volume: 104
Unit price:
2.835 EUR

(73):
Volume: 31
Unit price:
2.835 EUR

(74):
Volume: 47
Unit price:
2.835 EUR

(75):
Volume: 89
Unit price:
2.835 EUR

(76):
Volume: 76
Unit price:
2.835 EUR

(77):
Volume: 75
Unit price:
2.835 EUR

(78):
Volume: 21
Unit price:
2.835 EUR

(79):
Volume: 10
Unit price:
2.835 EUR

(80):
Volume: 68
Unit price:
2.835 EUR

(81):
Volume: 97
Unit price:
2.835 EUR

(82):
Volume: 75
Unit price:
2.835 EUR

(83):
Volume: 75
Unit price:
2.835 EUR

(84):
Volume: 43
Unit price:
2.835 EUR

(85):
Volume: 85
Unit price:
2.835 EUR

(86):
Volume: 68
Unit price:
2.835 EUR

(87):
Volume: 143
Unit price:
2.835 EUR

(88):
Volume: 85
Unit price:
2.835 EUR

(89):
Volume: 43
Unit price:
2.835 EUR

(90):
Volume: 9
Unit price:
2.835 EUR

(91):
Volume: 71
Unit price:
2.835 EUR

(92):
Volume: 18
Unit price:
2.835 EUR

(93):
Volume: 135
Unit price:
2.835 EUR

(94):
Volume: 47
Unit price:
2.835 EUR

(95):
Volume: 89
Unit price:
2.835 EUR

(96):
Volume: 182
Unit price:
2.835 EUR

(97):
Volume: 21
Unit price:
2.835 EUR

(98):
Volume: 68
Unit price:
2.835 EUR

(99):
Volume: 97
Unit price:
2.835 EUR

(100):
Volume: 153
Unit price:
2.835 EUR

(101):
Volume: 75
Unit price:
2.835 EUR

(102):
Volume: 43
Unit price:
2.835 EUR

(103):
Volume: 228
Unit price:
2.835 EUR

(104):
Volume: 43
Unit price:
2.835 EUR

(105):
Volume: 94
Unit price:
2.835 EUR

(106):
Volume: 71
Unit price:
2.835 EUR

(107):
Volume: 147
Unit price:
2.835 EUR

(108):
Volume: 6
Unit price:
2.835 EUR

(109):
Volume: 47
Unit price:
2.835 EUR

(110):
Volume: 271
Unit price:
2.835 EUR

(111):
Volume: 68
Unit price:
2.835 EUR

(112):
Volume: 271
Unit price:
2.835 EUR

(113):
Volume: 75
Unit price:
2.835 EUR

(114):
Volume: 271
Unit price:
2.835 EUR

(115):
Volume: 143
Unit price:
2.835 EUR

(116):
Volume: 71
Unit price:
2.835 EUR

(117):
Volume: 147
Unit price:
2.835 EUR

(118):
Volume: 918
Unit price:
2.835 EUR

(119):
Volume: 175
Unit price:
2.835 EUR

(120):
Volume: 73
Unit price:
2.815 EUR

(121):
Volume: 358
Unit price:
2.8 EUR

(122):
Volume: 168
Unit price:
2.8 EUR

(123):
Volume: 129
Unit price:
2.8 EUR

(124):
Volume: 120
Unit price:
2.835 EUR

(125):
Volume: 103
Unit price:
2.835 EUR

(126):
Volume: 272
Unit price:
2.835 EUR

(127):
Volume: 58
Unit price:
2.835 EUR

(128):
Volume: 133
Unit price:
2.835 EUR

(129):
Volume: 803
Unit price:
2.835 EUR

(130):
Volume:
1,034 Unit
price: 2.835
EUR

(131):
Volume: 167
Unit price:
2.83 EUR

(132):
Volume: 79
Unit price:
2.83 EUR

(133):
Volume: 137
Unit price:
2.83 EUR

(134):
Volume: 51
Unit price:
2.82 EUR

(135):
Volume: 46
Unit price:
2.82 EUR

(136):
Volume: 68
Unit price:
2.82 EUR

(137):
Volume: 541
Unit price:
2.82 EUR

(138):
Volume: 200
Unit price:
2.82 EUR

(139):
Volume: 200
Unit price:
2.82 EUR

(140):
Volume: 400
Unit price:
2.81 EUR

(141):
Volume: 8
Unit price:
2.8 EUR

(142):
Volume: 14
Unit price:
2.8 EUR

(143):
Volume: 27
Unit price:
2.8 EUR

(144):
Volume: 7
Unit price:
2.8 EUR

(145):
Volume: 85
Unit price:
2.8 EUR

(146):
Volume: 43
Unit price:
2.8 EUR

(147):
Volume: 71
Unit price:
2.8 EUR

(148):
Volume: 4
Unit price:
2.8 EUR

(149):
Volume: 22
Unit price:
2.8 EUR
d. Aggregated information 25,000

- Aggregated Volume Volume weighted
average price of
- Price €2.8213
e. Date of the transaction 5 April, 2022
f. Place of the transaction Nasdaq First North
Growth Market

For more information please contact:

Media / Investor Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com

investor.relations@faron.com

Phone: +1 (610) 529-6219

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com

Phone: +44 (0)20 3709 5700

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.